Kalshi Is Set to Start Taking Bets on Drug Trials
THE SO WHAT
Letting retail traders bet on drug trial outcomes expands the surface area for information leakage and market manipulation in biotech. If you operate in or around clinical data, tighten access controls and comms discipline—your timelines just became a speculative asset.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechSWISSto12 raised $70M, and it is that rare thing: a profitable space startup
A profitable space-hardware company raising $70M on top of €84.8M from ESA shows sovereign customers will bankroll dual-use infrastructure that can stand on its own P&L. If you’re building in space or other capex-heavy domains, anchoring around government-backed programs is still the cleanest path to durable margins.
Deep & Emerging Tech47 requests, zero answers — How Proton VPN keeps saying no to data demands
Forty-seven data requests and zero disclosures is a live proof that audited no-logs architectures can withstand legal pressure. If your product markets on privacy, you need this level of technical and policy alignment—not just a line in the FAQ.
Deep & Emerging TechCarney Taps General Dynamics for $1.4 Billion Canada Armored Vehicle Deal
Canada’s C$2 billion, four-year armored vehicle order is another data point that defense industrial capacity is being rebuilt as a long-term program, not a one-off spike. If you’re in manufacturing, materials, or autonomy adjacent to defense, expect more multi-year procurement that rewards reliability and compliance over speed alone.
Deep & Emerging TechAST SpaceMobile’s stock is sinking as the SpaceX rival looks to raise more cash
Space-based telecom remains brutally capital-intensive — AST SpaceMobile delaying launches while seeking more cash underlines how long these bets can stay pre-scale. If your product depends on non-terrestrial connectivity, treat these timelines as uncertain and design for graceful degradation on existing networks.